Nipocalimab
Published , updated
Unassigned
New Medicines
Autoimmune haemolytic anaemia, warm type
Information
New molecular entity
Janssen
Momenta
Development and Regulatory status
None
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Category
FcRn inhibitor to reduce circulating IgG antibodies
Incidence of autoimmune haemolytic anaemia is 1 in 80,000 to 100,000 population/year in Caucasians. It is slightly more common in females than in males and typically presents in middle-aged and older individuals [2].
Autoimmune haemolytic anaemia, warm type
Bladder instillation